Key result
Spironolactone, metoprolol, and perindopril prevented STZ-induced metabolic abnormalities and cardiovascular complications in a neonatal rat model of diabetes.
Why the study?
Do spironolactone, atenolol, metoprolol, ramipril, and perindopril prevent cardiovascular complications in a neonatal rat model of diabetes?
Do spironolactone, atenolol, metoprolol, ramipril, and perindopril prevent cardiovascular complications in a neonatal rat model of diabetes?
In a neonatal rat model of diabetes, spironolactone, metoprolol, and perindopril were effective in preventing metabolic and cardiovascular complications, outperforming atenolol and ramipril.
The present study was carried out to study the effect of spironolactone, atenolol, metoprolol, ramipril and perindopril on cardiovascular complications in neonatal model of diabetes in rats, induced by administering 90 mg/kg streptozotocin (STZ), i.p. in 2-day-old rats. Our data suggest that spironolactone, metoprolol and perindopril prevent not only the STZ-induced metabolic abnormalities but also cardiovascular complications as evident from the reduction in cholesterol, triglyceride and decrease in cardiac hypertrophy which are the initial symptoms of congestive heart failure. Metoprolol and perindopril appears to be beneficial agents as compared to atenolol and ramipril.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2013) studied Type 2 diabetes-induced cardiovascular complications. Spironolactone, atenolol, metoprolol, ramipril and perindopril was evaluated on Cardiovascular complications (cholesterol, triglyceride, and cardiac hypertrophy). Spironolactone, metoprolol, and perindopril prevented STZ-induced metabolic abnormalities and cardiovascular complications in a neonatal rat model of diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: